Low Dose Radiotherapy in Primary Indolent Cutaneous B-cell Lymphoma

Primary indolent cutaneous B cell lymphomas (PCBCL) are rare: although data on outcomes and treatment are limited, traditionally they have been treated with radiation doses in excess of 24 Gy. Recently, some trials that patients with primary cutaneous indolent lymphoma managed with very low dose (4 Gy) RT (LDRT) have shown that high response rates and durable remission can be achieved; unfortunately, given the retrospective nature of these studies, the role of LDRT in indolent PMCL remains undefined. The objective of this retrospective multicentric trial is to investigate the efficacy of low-dose involved-field radiation therapy in patients with primary indolent cutaneous B-cell Lymphoma.

NCT Number	NCT07310745
Lead Sponsor	Azienda USL Reggio Emilia - IRCCS
Conditions	Primary Indolent Cutaneous B-cell Lymphoma
Enrollment	52 participants
Start Date	2025-12-18
Primary Completion	2025-12-18 (estimated)
Study Completion	2026-12 (estimated)
Updated on ClinicalTrials.gov	2026-04-23